NCT00069251

Brief Summary

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2003

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2003

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 18, 2003

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 24, 2003

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2005

Completed
Last Updated

January 12, 2017

Status Verified

July 1, 2008

First QC Date

September 18, 2003

Last Update Submit

January 11, 2017

Conditions

Amphetamine-Related Disorders

Keywords

amphetamine dependence

Outcome Measures

Primary Outcomes (2)

  • Severity addiction

  • Methamphetamine use

Interventions

BupropionDRUG

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
  • Subject must be willing to comply with study procedures.
  • Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
  • Be able to comply with protocol requirements

You may not qualify if:

  • Please contact site for more information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Matrix Institute on Addictions

Costa Mesa, California, 92627, United States

Location

South Bay Treatment Center

San Diego, California, 92105, United States

Location

Pacific Addiction Research Center

Honolulu, Hawaii, 96813, United States

Location

Powell Chemical Dependency Center

Des Moines, Iowa, 50316, United States

Location

University of Missouri - Kansas City

Kansas City, Missouri, 64108, United States

Location

MeSH Terms

Conditions

Amphetamine-Related Disorders

Interventions

Bupropion

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PropiophenonesKetonesOrganic Chemicals

Study Officials

  • Richard Rawson, Ph.D.

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NIH

Study Record Dates

First Submitted

September 18, 2003

First Posted

September 24, 2003

Study Start

July 1, 2003

Study Completion

June 1, 2005

Last Updated

January 12, 2017

Record last verified: 2008-07

Locations

US(5)